EpiBiologics launched in 2023 with a $50 million series A, having been founded to take forward the work of renowned antibody ...

The team brings a strong balance of scientific and commercial expertise, has built a unique data foundation with a ...

Amgen is adding Dark Blue to its tapestry, embedding the U.K. biotech’s preclinical blood cancer program into its ...

Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has ...

Inside the race to turn one of cell biology’s least understood processes into a new foundation for drug development and ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

Hydrolyzed Vegetable Protein Market is expected to reach US$ 5,110.8 Mn by 2035, driven by rising demand for plant-based ...

The companies Kymera Therapeutics, Immunovant, and Dyne Therapeutics bagged the biggest biotech funding rounds overall in ...

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) is one of the stocks under $1 that will explode. On January 8, 2026, TheFly reported ...

Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutationsKB407 transduction confirmed in all ...

Alveus Therapeutics said on Thursday it has raised $159.8 million in funding to develop obesity treatments focused on helping patients keep weight off long-term, a problem the company says current ...

The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that ...